Research and Markets: Dr. Reddy's Laboratories Generics Company Intelligence Report Available Now

Business Wire, June 13, 2008

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/af884d/dr_reddys_laborato) has announced the addition of the "Dr. Reddy's Laboratories Generics Company Intelligence Report" companyprofile to their offering.

Dr. Reddy's is the second largest pharmaceutical manufacturer in India, behind Ranbaxy. The company sells APIs, branded drugs and generics. Most of its branded drugs are copies of drugs patented in the West, but not in India.

The company's current best selling products include ramipril (Altace, King Pharmaceuticals), first introduced in non-US markets in 2003, and simvastatin, which the firm sells through an authorised generics agreement with Merck & Co. The company has made efforts to break into the US market with mixed results. It has had a few ANDAs approved, for major products such as ciprofloxacin, fluconazole and citalopram.

Dr. Reddy's is also represented in western Europe, Russia and Asia. In 2002, the company made its first overseas acquisitions, both in the UK. In November 2005, Dr. Reddy's announced it had signed a definitive agreement to acquire Roche's API business in Cuernavaca, Mexico. In March 2006, Dr. Reddy's completed its purchase of the German generic pharmaceutical firm, betapharm, from 3i, in a deal worth 480 million euros in cash. In 2007, the company announced that it was making the UK its European headquarters.

Executive Summary:

Espicoms generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the companys active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Key Topics Covered:

For more information visit http://www.researchandmarkets.com/research/af884d/dr_reddys_laborato

Source: Espicom Business Intelligence Ltd